Dr. Yotam Levin has been the CEO of NanoPass Technologies Ltd. since 2002.  He is in charge of the Company’s strategy, business development and all clinical activities. Under his supervision the company successfully licensed its product with the FDA and the European authorities, and conducted pioneering intradermal vaccination studies. Prior to becoming CEO at NanoPass, Dr Levin was head of the biomedical consulting practice at Global Business Solutions, an Israeli strategic consulting firm. Dr Levin holds an MD degree and an MBA (finance), both from Tel Aviv University, Israel. Dr Levin authored several key publications in leading journals such as the Lancet Infectious Diseases, Vaccine, JID and HV&I, and participated in authoring over two-dozen patent applications. He serves as a frequent reviewer for Vaccine, Journal of Infectious diseases (JID) and Human Vaccines & Immunotherapeutics (HV&I), and was a Guest Editor for Vaccine’s Skin Vaccination Summit 2015. In his spare time, he runs marathons, teaches biomedical entrepreneurship and volunteers with a disabled children NPO.  

Vaccines & Immunotherapeutics